AiRuiKa (camrelizumab) / CG Invites, Jiangsu Hengrui Pharma, HLB Bio Group, NPO Petrovax - LARVOL DELTA

Camrelizumab-Based Therapy-Induced RCCEP in Advanced NSCLC Patients: A Pooled Analysis of Two Phase III Registration Trials (IASLC-WCLC 2025) - P3 | "The CameL study enrolled patients with stage IIIB-IV non-squamous NSCLC without EGFR or ALK alterations, treated with camrelizumab combined with chemotherapy comprising pemetrexed and carboplatin. The CameL-sq study included patients with stage IIIB-IV squamous NSCLC receiving camrelizumab plus chemotherapy consisting of paclitaxel and carboplatin...Conclusions : This pooled analysis confirmed that RCCEP was relatively prevalent yet predominantly mild in severity among advanced NSCLC patients treated with camrelizumab-based regimens. Notably, the emergence of RCCEP positively correlated with enhanced efficacy, evidenced by improved ORR, prolonged PFS and OS, underscoring RCCEP as a potential predictive biomarker for therapeutic efficacy."

IO biomarker • Metastases • P3 data • Retrospective data • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Solid Tumor • ALK • EGFR

Phase 2 CAPSTONE trial of first-line camrelizumab plus famitinib for locally advanced or metastatic pulmonary sarcomatoid carcinomas (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Oncology • Sarcoma • Solid Tumor

Efficacy and safety of camrelizumab plus apatinib for solid tumors: a meta-analysis (Frontiers) - "The Objective Response Rate (ORR) was 40.0%, with a Disease Control Rate (DCR) of 78.0%. Overall Survival (OS) rates at 6, 12, and 24 months were 79.0%, 46.5%, and 16.0%, respectively. Progression-Free Survival (PFS) rates at the same intervals were 48.4%, 19.8%, and 6.7%."

Retrospective data • Oncology • Solid Tumor

A Phase II Trial of Induction Camrelizumab Plus Chemotherapy Followed by Chemoradiotherapy and Consolidation in Limited-Stage SCLC (IASLC-WCLC 2025) - P2 | "Although durvalumab consolidation has enhanced outcomes compared to traditional concurrent chemoradiotherapy (CRT), disease progression remains a formidable challenge...Patients were randomly assigned (1:1) to either an experimental regimen of induction immunotherapy and chemotherapy (two cycles of camrelizumab plus etoposide-platinum [EP] or etoposide-carboplatin [EC]) followed by CRT, prophylactic cranial irradiation (PCI), and up to 12 months of camrelizumab consolidation (camrelizumab group), or a control regimen of induction chemotherapy (EP or EC) followed by CRT and PCI (cCRT group)...Conclusions : These findings suggest that induction camrelizumab plus chemotherapy followed by CRT and camrelizumab consolidation may improve both PFS and OS in LS-SCLC without exacerbating toxicity. Further research to refine treatment sequencing could provide vital improvements in managing this challenging disease."

P2 data • Lung Cancer • Non Small Cell Lung Cancer • Pneumonia • Small Cell Lung Cancer • Solid Tumor

A Study of SHR-1802 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P2 | N=25 | Terminated | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | N=124 ➔ 25 | Recruiting ➔ Terminated; Adjustment of R&D strategy

Enrollment change • Trial termination • Solid Tumor

LEAF-02: Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab (clinicaltrials.gov) - P2 | N=141 | Recruiting | Sponsor: Fudan University | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor

Efficacy and Safety of Camrelizumab and Apatinib in Combination with IMRT in Unresectable Hepatocellular Carcinoma: A Non-Randomised Phase 2 Study (ASTRO 2025) - No abstract available

Clinical • Combination therapy • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial. (PubMed, Eur J Cancer) - P2 | "NCRCN regimen was a promising treatment strategy with a high surgical conversion rate in initially inoperable patients with LAESCC. TRIAL REGISTRATION CLINICALTRIALS."

Journal • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Disorder • Hematological Disorders • Neutropenia • Oncology • Squamous Cell Carcinoma • CD8 • FOXP3

Neoadjuvant Camrelizumab with Chemotherapy in PD-L1-Negative Locally Advanced Cervical Cancer: An Open-Label, Multi-Center, Single-Arm, Phase 2 Trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Cervical Cancer • Oncology • Solid Tumor

TASK-05: HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) (clinicaltrials.gov) - P2 | N=45 | Recruiting | Sponsor: Fudan University | Not yet recruiting ➔ Recruiting

Enrollment open • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Oncology • Solid Tumor

LEAF-02: Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab (clinicaltrials.gov) - P2 | N=141 | Not yet recruiting | Sponsor: Fudan University

New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer (clinicaltrials.gov) - P3 | N=435 | Not yet recruiting | Sponsor: Tao Zhang

New P3 trial • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

A Phase II Study of Camrelizumab Plus Docetaxol in Advanced NCSLC Pre-Treated With Immune Checkpoint Inhibitors and Chemotherapy (IASLC-WCLC 2025) - "Patients with PD-L1 TPS≥50% or those who develop RCCEP are more likely to benefit from this treatment. However, the small sample size is a limitation of this study, and further research with a larger cohort is needed to confirm those findings and achieve statistical significance."

Checkpoint inhibition • IO biomarker • Metastases • P2 data • Fatigue • Oncology • Solid Tumor • Squamous Cell Carcinoma

First-Line Camrelizumab Plus Chemotherapy in 3004 Patients With Advanced Non-Squamous NSCLC: A Nationwide Retrospective Study (IASLC-WCLC 2025) - "These large-scale data supported the application of this combination strategy for a broader population in clinical practice. The study is ongoing to enroll more patients and extend follow-up, and 3- to 5-year real-world OS rates will be reported in the future."

Metastases • Retrospective data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Solid Tumor

Induction-Concurrent Chemoradiotherapy with or without Camrelizumab for Postoperative Residual High-Grade Gliomas: An Open, Randomized, Phase II Clinical Study (ASTRO 2025) - No abstract available

Clinical • P2 data • Brain Cancer • Glioma • High Grade Glioma • Solid Tumor

Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Hebei Medical University Fourth Hospital | N=162 ➔ 90

Enrollment change • pMMR • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

Phase II Clinical Trial of Trilaciclib in Combination With PD-1 Inhibitor and Chemotherapy as First-Line Treatment for (NSCLC) (IASLC-WCLC 2025) - P2 | "The primary endpoint was progression-free survival (PFS), and the key secondary endpoints were antitumor efficacy (ORR, DCR, OS, etc.) and bone marrow protection efficacy (incidence of grade 3 neutropenia during chemotherapy; Incidence of ≥ grade 3 thrombocytopenia; Incidence of grade 3 anemia, etc.), safety and tolerability. Methods : Medication plan is Trilaciclib 240mg/m 2 intravenously for 30 minutes and administered within 4 hours before chemotherapy; Pembrolizumab 200mg Q3W; Or Camrelizumab 200mg Q3W; Or Tislelizumab 200mg Q3W; Or Sintilimab 200mg Q3W; Or Toripalimab 240mg Q3W; Pemetrexed (non-squamous cell carcinoma) is 500mg/m 2 Q3W; Paclitaxel Albumin-bound (squamous cell carcinoma) is 260mg/m 2 Q3W; Carboplatin is AUC=5, up to 750mg Q3W; At present, this study has passed the Medical Ethics Committee of Liaoning Cancer Hospital, and has completed registration in the Chinese Clinical Trial Registry, The registration number is ChiCTR2500098340.It is expected..."

Clinical • Combination therapy • IO biomarker • P2 data • Anemia • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Neutropenia • Non Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • Thrombocytopenia

Perioperative Camrelizumab plus Rivoceranib in Resectable Hepatocellular Carcinoma (CARES-009): A Randomized, Multicenter, Phase 3 Trial (ESMO 2025) - No abstract available

Clinical • P3 data • Hepatocellular Cancer • Oncology • Solid Tumor

Effectiveness and Safety of Camrelizumab Plus Rivoceranib Combined With TACE With or Without HAIC in First-Line Treatment of Unresectable Hepatocellular Carcinoma (ESMO 2025) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

HCC-IM-1: Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment (clinicaltrials.gov) - P=N/A | N=150 | Not yet recruiting | Sponsor: Fudan University

New trial • Hepatocellular Cancer • Oncology • Solid Tumor

CamPacBTC: Second-line treatment of camrelizumab combined with nab-paclitaxel in advanced biliary tract cancer: an exploratory study (ChiCTR) - P=N/A | N=63 | Suspended | Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University | Recruiting ➔ Suspended

Trial suspension • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer. (PubMed, BMC Gastroenterol) - "Forty-three patients with advanced gastric cancer receiving PD-1 inhibitors (including camrelizumab, sintilimab, and tislelizumab, 200 mg every 3 weeks) combined with chemotherapy were retrospectively enrolled. No abstract available"

Journal • Gastric Cancer • Oncology • Solid Tumor

A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

New P2 trial • Cervical Cancer • Oncology • Solid Tumor

A Phase II Trial of Induction Camrelizumab Plus Chemotherapy Followed by Chemoradiotherapy and Consolidation in Limited-Stage SCLC (IASLC-WCLC 2025) - P2 | "Although durvalumab consolidation has enhanced outcomes compared to traditional concurrent chemoradiotherapy (CRT), disease progression remains a formidable challenge...Patients were randomly assigned (1:1) to either an experimental regimen of induction immunotherapy and chemotherapy (two cycles of camrelizumab plus etoposide-platinum [EP] or etoposide-carboplatin [EC]) followed by CRT, prophylactic cranial irradiation (PCI), and up to 12 months of camrelizumab consolidation (camrelizumab group), or a control regimen of induction chemotherapy (EP or EC) followed by CRT and PCI (cCRT group)...Conclusions : These findings suggest that induction camrelizumab plus chemotherapy followed by CRT and camrelizumab consolidation may improve both PFS and OS in LS-SCLC without exacerbating toxicity. Further research to refine treatment sequencing could provide vital improvements in managing this challenging disease."

P2 data • Lung Cancer • Non Small Cell Lung Cancer • Pneumonia • Small Cell Lung Cancer • Solid Tumor

Treatment Strategies for First-Line PD-L1-Unselected Advanced NSCLC: A Comparative Review of Immunotherapy-Based Regimens by PD-L1 Expression and Clinical Indication. (PubMed, Diagnostics (Basel)) - " PD-1-targeted therapies demonstrated superior OS compared to PD-L1-based regimens, with cemiplimab monotherapyranking highest for OS benefit (posterior probability: 90%), followed by sintilimab plus platinum-based chemotherapy (PBC) and pemetrexed-PBC. PFS atezolizumab plus bevacizumab and PBC, and camrelizumab plus PBC were the most effective regimens...The most favorable safety profiles were observed with cemiplimab, nivolumab, and avelumab monotherapy, while atezolizumab plus PBC and sugemalimab plus PBC carried the highest toxicity burdens...Balancing efficacy with safety remains critical, especially in the absence of predictive biomarkers. These findings support a patient-tailored approach to immunotherapy and highlight the need for further biomarker-driven and real-world investigations to optimize treatment selection."

IO biomarker • Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor